Similar articles

• [Roles of cytokines and growth factors in diabetic retinopathy].

  Yamashita H, Yamamoto T. Yamashita H, et al. Nihon Rinsho. 2005 Jun;63 Suppl 6:202-6. Nihon Rinsho. 2005. PMID: 15999707 Review. Japanese. No abstract available.
• [Role of advanced glycation end products and activation of PKC in diabetic retinopathy].

  Kaji Y, Oshika T. Kaji Y, et al. Nihon Rinsho. 2005 Jun;63 Suppl 6:188-93. Nihon Rinsho. 2005. PMID: 15999705 Review. Japanese. No abstract available.
• Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.

  Endo M, Yanagisawa K, Tsuchida K, Okamoto T, Matsushita T, Higuchi M, Matsuda A, Takeuchi M, Makita Z, Koike T. Endo M, et al. Horm Metab Res. 2001 May;33(5):317-22. doi: 10.1055/s-2001-15122. Horm Metab Res. 2001. PMID: 11440280
• VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

  Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA. Saishin Y, et al. J Cell Physiol. 2003 May;195(2):241-8. doi: 10.1002/jcp.10246. J Cell Physiol. 2003. PMID: 12652651
• [Chronic complications due to diabetes mellitus: Pathology of diabetic retinopathy].

  Hata Y, Ishibashi T. Hata Y, et al. Nihon Rinsho. 2002 Oct;60 Suppl 10:155-61. Nihon Rinsho. 2002. PMID: 12430222 Review. Japanese. No abstract available.